Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Amitiza 24microgram capsules
0106070C0BBAAAA
|
Amitiza | Lubiprostone | Gastro-Intestinal System | No data available |
|
Anacal rectal ointment
0107010J0BBABAB
|
Anacal | Heparinoid | Gastro-Intestinal System | No data available |
|
Anacal suppositories
0107010J0BBAAAA
|
Anacal | Heparinoid | Gastro-Intestinal System | No data available |
|
Andrews Antacid chewable tablets
0101010F0BBAAA0
|
Andrews (Magnesium carbonate) | Magnesium carbonate | Gastro-Intestinal System | No data available |
|
Antacid & Oxetacaine oral suspension (old)
0101010N0AAAAAA
|
Antacid and oxetacaine | Aluminium and magnesium and oxetacaine | Gastro-Intestinal System | No data available |
|
Antepsin 1g tablets
0103030S0BBAAAA
|
Antepsin | Sucralfate | Gastro-Intestinal System | No data available |
|
Antepsin 1g/5ml oral suspension
0103030S0BBABAD
|
Antepsin | Sucralfate | Gastro-Intestinal System | No data available |
|
Anugesic HC cream
0107020J0BBAAAA
|
Anugesic HC | Hydrocortisone | Gastro-Intestinal System | No data available |
|
Arret 2mg capsules
0104020L0BDAAAA
|
Arret | Loperamide hydrochloride | Gastro-Intestinal System | No data available |
|
Asacol 1g/application foam enema
0105010B0BBAEAK
|
Asacol | Mesalazine (Systemic) | Gastro-Intestinal System | No data available |
|
Asacol 250mg suppositories
0105010B0BBADAG
|
Asacol | Mesalazine (Systemic) | Gastro-Intestinal System | No data available |
|
Asilone Antacid chewable tablets
0101010L0BBADA0
|
Asilone | Aluminium and magnesium and activated simeticone | Gastro-Intestinal System | No data available |
|
Asilone Antacid liquid
0101010L0BBAEAA
|
Asilone | Aluminium and magnesium and activated simeticone | Gastro-Intestinal System | No data available |
|
Asilone Heartburn chewable tablets
0101021B0BHABAC
|
Asilone Heartburn | Alginic acid compound preparations | Gastro-Intestinal System | No data available |
|
Asilone Heartburn liquid
0101021B0BHAAAI
|
Asilone Heartburn | Alginic acid compound preparations | Gastro-Intestinal System | No data available |
|
Asilone oral suspension
0101010L0BBABAA
|
Asilone | Aluminium and magnesium and activated simeticone | Gastro-Intestinal System | No data available |
|
Asilone Windcheaters 100mg capsules
0101010R0BBAAAA
|
Asilone Windcheater | Simeticone | Gastro-Intestinal System | No data available |
|
Atropine 100micrograms/5ml oral solution
0102000ACAAAVAV
|
Atropine sulfate (Oral) | Atropine sulfate | Gastro-Intestinal System | No data available |
|
Atropine 150micrograms/5ml oral solution
0102000ACAAAXAX
|
Atropine sulfate (Oral) | Atropine sulfate | Gastro-Intestinal System | No data available |
|
Atropine 200micrograms/5ml oral solution
0102000ACAAAQAQ
|
Atropine sulfate (Oral) | Atropine sulfate | Gastro-Intestinal System | No data available |
|
Atropine 250micrograms/5ml oral liquid
0102000ACAAAZAZ
|
Atropine sulfate (Oral) | Atropine sulfate | Gastro-Intestinal System | No data available |
|
Atropine 300micrograms/5ml oral liquid
0102000ACAAASAS
|
Atropine sulfate (Oral) | Atropine sulfate | Gastro-Intestinal System | No data available |
|
Atropine 400micrograms/5ml oral liquid
0102000ACAAAWAW
|
Atropine sulfate (Oral) | Atropine sulfate | Gastro-Intestinal System | No data available |
|
Atropine 50micrograms/5ml oral solution
0102000ACAAATAT
|
Atropine sulfate (Oral) | Atropine sulfate | Gastro-Intestinal System | No data available |
|
Atropine 5mg/5ml oral solution
0102000ACAAAYAY
|
Atropine sulfate (Oral) | Atropine sulfate | Gastro-Intestinal System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.